Evidence map›Paper›PMID 31953433›Full record

ArticleScientific reports2020

Statin use, HMGCR expression, and breast cancer survival - The Malmö Diet and Cancer Study.

Olöf Bjarnadottir, Maria Feldt, Maria Inasu, Pär-Ola Bendahl, Karin Elebro, Siker Kimbung, Signe Borgquist

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed, 6 pooled it
2.2field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 6 syntheses or guidelines pooled it, 49 citations in OpenAlex.

  1. Statins and prognosis of female breast cancer: a meta-analysis.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2025
    Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Trial
  8. Review
  9. Article
  10. Review
  11. Review
  12. Article
  13. Review
  14. Lipids: Driving Forces in the Underlying Biology of Carcinogenesis.ACS pharmacology & translational science · 2025
    Review
  15. Simultaneous visualization of membrane fluidity and morphology defines adhesion signatures of cancer cells.Proceedings of the National Academy of Sciences of the United States of America · 2024
    Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Olöf BjarnadottirDivision of Oncology and Pathology, Department of Clinical Sciences, Lund University, Lund, Sweden. olof.bjarnadottir@med.lu.se.
Maria FeldtDivision of Oncology and Pathology, Department of Clinical Sciences, Lund University, Lund, Sweden.
Maria InasuDivision of Oncology and Pathology, Department of Clinical Sciences, Lund University, Lund, Sweden.
Pär-Ola BendahlDivision of Oncology and Pathology, Department of Clinical Sciences, Lund University, Lund, Sweden.
Karin ElebroDivision of Oncology and Pathology, Department of Clinical Sciences, Lund University, Lund, Sweden.
Siker KimbungDivision of Oncology and Pathology, Department of Clinical Sciences, Lund University, Lund, Sweden.
Signe BorgquistDivision of Oncology and Pathology, Department of Clinical Sciences, Lund University, Lund, Sweden.
Lund University · SEAarhus University Hospital · DKSkåne University Hospital · SE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Statins, commonly used to treat hypercholesterolemia, have also been proposed as anti-cancer agents. The identification of a predictive marker is essential. The 3-hydroxy-3-methylglutaryl-coenzyme-A reductase (HMGCR), which is inhibited by statins, might serve as such a marker. Thorough antibody validation was performed for four different HMGCR antibodies. Tumor expression of HMGCR (#AMAb90619, CL0260, Atlas Antibodies, Stockholm, Sweden) was evaluated in the Malmö Diet and Cancer Study breast cancer cohort. Statin use and cause of death data were retrieved from the Swedish Prescribed Drug Register and Swedish Death Registry, respectively. Breast cancer-specific mortality (BCM) according to statin use and HMGCR expression were analyzed using Cox regression models. Three-hundred-twelve of 910 breast cancer patients were prescribed statins; 74 patients before and 238 after their breast cancer diagnosis. HMGCR expression was assessable for 656 patients; 119 showed negative, 354 weak, and 184 moderate/strong expressions. HMGCR moderate/strong expression was associated with prognostically adverse tumor characteristics as higher histological grade, high Ki67, and ER negativity. HMGCR expression was not associated with BCM. Neither was statin use associated with BCM in our study. Among breast cancer patients on statins, no or weak HMGCR expression predicted favorable clinical outcome. These suggested associations need further testing in larger cohorts.

Indexed as

AgedAged, 80 and overBreast NeoplasmsFemaleHumansHydroxymethylglutaryl-CoA Reductase InhibitorsHydroxymethylglutaryl CoA ReductasesMiddle AgedPrognosisRegistriesSurvival AnalysisSwedenUp-RegulationHMGCR protein, humanHydroxymethylglutaryl-CoA Reductase InhibitorsHydroxymethylglutaryl CoA Reductases

Identifiers

PMID31953433
PMCPMC6969108
OpenAlexW2999854125

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.